Kos Biotechnology Partners Invests in Fathom Therapeutics

Kos Biotechnology Partners has joined Sutter Hill Ventures in a new funding round for Fathom Therapeutics. The New York-based company, formerly known as Atommap Corp., uses a physics and AI-powered platform for drug discovery. This investment supports the development of novel therapeutic candidates. The capital aims to accelerate early-stage research and improve the accuracy of target identification.

Expanding Lab-in-the-Loop Discovery Capabilities

The new financing brings Fathom Therapeutics’ total funding to more than $100 million. This capital provides the resources needed to expand operational capabilities. The company plans to scale its lab-in-the-loop technology.

This system allows real-time feedback between computational models and physical laboratory experiments. Such integration is critical for validating AI predictions in a biological context.

The funds will also support the expansion of internal discovery programs. These programs focus on high-value therapeutic areas where traditional methods have struggled. By enhancing its internal pipeline, Fathom aims to generate proprietary assets with strong commercial potential.

The emphasis on lab-in-the-loop systems highlights a shift toward more iterative and data-rich discovery processes. This approach helps researchers refine their models continuously based on empirical data.

AI in Drug Discovery Market Growth

The broader context for this investment is the rapid expansion of artificial intelligence in pharmaceutical research. According to TrendX Insights’ AI in Drug Discovery Market, the market is projected to reach USD 8.36 Bn by 2034. This growth represents a compound annual growth rate of 17.40% from the 2025 baseline of USD 1.97 Bn. Such projections indicate strong investor and institutional interest in AI-driven solutions.

The sector is moving beyond simple data analysis to active target identification and molecule design. Companies like Fathom are at the forefront of this technological transition. The ability to simulate molecular interactions with high precision offers a competitive advantage.

This technology can significantly lower the cost of early-stage research and development. As a result, more biotech firms are adopting similar AI-centric platforms to stay competitive.

Strategic Implications for Biotech Investment

This investment by Kos Biotechnology Partners signals a strategic focus on next-generation discovery tools. The firm is positioning itself to capitalize on the efficiency gains offered by AI. By backing Fathom, Kos gains exposure to a platform that could streamline its own portfolio companies’ R&D efforts.

The collaboration between venture capital and specialized biotech firms is becoming increasingly common. Investors are seeking partners who can provide both capital and technical expertise.

Fathom’s physics-based approach differentiates it from purely data-driven AI competitors. This hybrid model may offer greater reliability in predicting biological outcomes. The expansion of internal discovery programs suggests a move toward self-sufficiency in early-stage asset generation.

This strategy reduces reliance on external licensing and allows for greater control over intellectual property. The focus on high-value therapeutic areas indicates a targeted approach to maximizing return on investment.

Future Outlook for Fathom Therapeutics

Fathom Therapeutics is well-positioned to leverage its expanded resources for rapid growth. The company will likely continue to refine its AI models and laboratory workflows. Success in this area could lead to the identification of novel drug candidates.

These candidates may then progress through preclinical and clinical stages. The integration of physics and AI remains a key differentiator in the crowded biotech space.

As the company scales, it will need to manage the complexity of its data infrastructure. Maintaining high standards of data quality and reproducibility will be essential. The broader market trends suggest that AI in drug discovery will play a central role in future pharmaceutical innovation.

Fathom’s ability to execute on its strategic plan will determine its long-term success. The industry is watching closely to see if this platform can deliver tangible results in the clinic.